Metastatic Castration-Resistant Prostate Cancer Market - A Global and Regional Analysis

2.1    North America
         2.1.1    Market Dynamics
         2.1.2    Market Sizing and Forecast
               2.1.2.1    North America Metastatic Castration-Resistant Prostate Cancer Market, by Country
                        2.1.2.1.1    U.S.
2.2    Europe
         2.2.1    Market Dynamics
         2.2.2    Market Sizing and Forecast
               2.2.2.1    Europe Metastatic Castration-Resistant Prostate Cancer Market, by Country
                        2.2.2.1.1    U.K.
                        2.2.2.1.2    Germany
                        2.2.2.1.3    France
                        2.2.2.1.4    Italy
                        2.2.2.1.5    Spain
                        2.2.2.1.6    Rest-of -Europe
2.3    Asia-Pacific
         2.3.1    Market Dynamics
         2.3.2    Market Sizing and Forecast
               2.3.2.1    Asia-Pacific Metastatic Castration-Resistant Prostate Cancer Market, by Country
                        2.3.2.1.1    Japan
                        2.3.2.1.2    Rest-of-Asia-Pacific
2.4    Rest-of-the-World
         2.4.1    Market Dynamics
         2.4.2    Market Sizing and Forecast

3.1    Key Developments and Strategies
         3.1.1    Funding Activities
         3.1.2    Mergers and Acquisitions
         3.1.3    Regulatory Approvals
         3.1.4    Partnerships, Collaborations, and Business Expansions
3.2    Company Profiles
         3.2.1    Pfizer, Inc.
               3.2.1.1    Company Overview
               3.2.1.2    Product Portfolio
               3.2.1.3    Target Customers/End Users
               3.2.1.4    Analyst View
         3.2.2    Astellas Pharma Inc.
               3.2.2.1    Company Overview
               3.2.2.2    Product Portfolio
               3.2.2.3    Target Customers/End Users
               3.2.2.4    Analyst View
         3.2.3    Merck & Co., Inc.
               3.2.3.1    Company Overview
               3.2.3.2    Product Portfolio
               3.2.3.3    Target Customers/End Users
               3.2.3.4    Analyst View
         3.2.4    AstraZeneca
               3.2.4.1    Company Overview
               3.2.4.2    Product Portfolio
               3.2.4.3    Target Customers/End Users
               3.2.4.4    Analyst View
         3.2.5    Sanofi
               3.2.5.1    Company Overview
               3.2.5.2    Product Portfolio
               3.2.5.3    Target Customers/End Users
               3.2.5.4    Analyst View
         3.2.6    Bayer Corporation
               3.2.6.1    Company Overview
               3.2.6.2    Product Portfolio
               3.2.6.3    Target Customers/End Users
               3.2.6.4    Analyst View
         3.2.7    Novartis, AG
               3.2.7.1    Company Overview
               3.2.7.2    Product Portfolio
               3.2.7.3    Target Customers/End Users
               3.2.7.4    Analyst View
         3.2.8    Others

Research Methodology

Table:    Market Snapshot
Table:    Market Dynamics
Table:    Global Metastatic Castration-Resistant Prostate Cancer Market (by Region), $Million, 2024-2035

Figure:    Metastatic Castration-Resistant Prostate Cancer Market (by Scenario), $Million, 2024, 2030, and 2035
Figure:    Global Metastatic Castration-Resistant Prostate Cancer Market, 2024 and 2035
Figure:    Global Metastatic Castration-Resistant Prostate Cancer Market Key Trends, Impact Analysis, 2024-2035
Figure:    North America Metastatic Castration-Resistant Prostate Cancer Market, $Million, 2024-2035 
Figure:    Europe Metastatic Castration-Resistant Prostate Cancer Market, $Million, 2024-2035 
Figure:    Asia-Pacific Metastatic Castration-Resistant Prostate Cancer Market, $Million, 2024-2035
Figure:    Rest-of-the-World Metastatic Castration-Resistant Prostate Cancer Market, $Million, 2024-2035